Xencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and Systemic Lupus Erythematosus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| XENCOR (NASDAQ: XNCR) | Delayed: 25.84 +0.68 (2.70%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.16 | 52 Week High | $26.50 | |||
| Open | $25.18 | 52 Week Low | $9.89 | |||
| Day High | $26.12 | P/E | N/A | |||
| Day Low | $24.71 | EPS | $-0.51 | |||
| Volume | 936,349 | |||||
